Skip to main content
. 2008 Aug 1;283(31):21325–21333. doi: 10.1074/jbc.M801593200

FIGURE 1.

FIGURE 1.

Egf1.0 inhibits PAP1 amidolytic activity. Recombinant Egf1.0, Egf1.0ΔRD, Egf1.0ΔCD, Egf1.0R51A, or Egf0.4 (4 pmol) was added to purified PAP-1 (0.4 pmol) plus substrate for 10 min. PAP1 plus substrate alone served as the control (Cont). The asterisk indicates treatment with significantly lower amidase activity compared with the control (F5, 17 = 20.2; p < 0.001; followed by Dunnett's multiple comparison procedure).